Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: One-year results of the ESSENCE study

Journal of the American College of Cardiology

Volumn 36, Issue 3, 2000, Pages 693-698

  Goodman, Shaun G ^a,i   Cohen, Marc ^b   Bigonzi, Frederique ^c   Gurfinkel, Enrique P ^d   Radley, David R ^c   Le Iouer, Veronique ^c   Fromell, Gregg J ^c   Demers, Christine ^e   Turpie, Alexander G G ^f   Califf, Robert M ^g   Fox, Keith A A ^h   Langer, Anatoly ^j  

^a UNIVERSITY OF TORONTO   (Canada)

^b ALLEGHENY UNIVERSITY HOSPITALS   (United States)

^c SANOFI   (France)

^d HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

^e LAVAL UNIVERSITY   (Canada)

^f MCMASTER UNIVERSITY   (Canada)

^g DUKE UNIVERSITY   (United States)

^h ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

ⁱ ST MICHAEL'S HOSPITAL   (Canada)

^j NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANGINA, UNSTABLE; DOUBLE-BLIND METHOD; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HEART CATHETERIZATION; HEPARIN; HUMANS; INCIDENCE; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; RECURRENCE;

EID: 0033861184     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)00808-1     Document Type: Article

References (17)

1. The pathogenesis of coronary artery disease and the acute coronary syndromes (2)
2. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: A meta-analysis
3. Low-molecular-weight heparin during instability in coronary artery disease
4. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for six weeks in the management of unstable coronary artery disease: FRagmin In unstable Coronary artery disease (FRIC) Study
5. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
6. Low-molecular-weight heparins
7. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia
8. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAXIS (FRAXiparine in Ischaemic Syndrome)
9. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
10. Enoxaparin for the acute and chronic management of unstable angina/non-Q wave myocardial infarction: Results of TIMI 11B
11. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis
12. Treatment benefit of enoxaparin in unstable angina/non-Q wave myocardial infarction is maintained at one year follow-up in TIMI 11B
13. Economic assessment of low molecular weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: Results from the ESSENCE randomized trial
14. Is the use of low-molecular-weight heparin (enoxaparin) in acute coronary syndrome patients cost saving in Canada?
15. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction
16. Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina
17. Long-term low molecular mass heparin in unstable coronary artery disease: FRISC II prospective randomised multicentre study